Guido Würth
Head of Corporate Development Radiopharma Affibody AB
Guido Wuerth joined Affibody AB in 2021 and leads Corporate Development for the company’s radiopharmaceutical portfolio, with responsibility for asset strategy and lifecycle management. He previously held senior clinical leadership roles at MorphoSys, where he served as Global Program Head and contributed to the U.S. approval of tafasitamab (MONJUVI®) and several major out licensing transactions. Earlier, Guido led Global Clinical Operations at Sandoz and was Global Program Medical Director for the etanercept biosimilar Erelzi®, with extensive regulatory interactions. He has also held senior roles at Baxter, Antisense Pharma, and Schwarz Pharma (now UCB). Guido is a board certified urologist and holds an MD from the University of Cologne, Germany.
Seminars
Join your colleagues for a deep-dive discussion in smaller groups to map out the next generation of TRP targets. You will brainstorm high-potential clinical candidates and cross-pollinate ideas from the ADC space to sharpen selection strategy before sharing your table’s thoughts and discussion back to the group.
- Identifying optimal tumor targets by evaluating density, internalization, and off-target risk
- Exploring current targets under development and their potential clinical impact
- Applying lessons from antibody-drug conjugates and other targeted therapies to guide RLT target selection
- Characterizing mechanisms of renal and hepatic injury associated with alpha-emitting radioligand therapies
- Evaluating clinical and molecular strategies to reduce off-target organ exposure and cumulative toxicity
- Guiding dosing, scheduling, and patient monitoring to enable safer clinical application of novel alpha emitters
Thinking about entering radiopharma – or wish you’d known more before you did? Join seasoned leaders from R&D, CMC, clinical, and commercial as they share hard-won lessons, practical pitfalls, and insider insights across the entire development journey, and bring your questions to those who’ve navigated it firsthand.
- R&D and Preclinical: novel target choices, targeting molecules, linkers, chelators, preclinical dosimetry and more
- CMC and Regulatory: isotope properties, differences in supply chain, logistics networks, CMC innovations, regulatory considerations and more
- Clinical Development: clinical trial design, working with sites, working with clinical stakeholders, patient centric approaches and more
